Cumberlege Review

Cumberlege Review
Name	Cumberlege Review
Date	2020–2022
Author	Julia Cumberlege, Baroness Cumberlege
Jurisdiction	United Kingdom
Published	2020; final report 2022
Subject	Patient safety; prescribed medicines; medical devices

Cumberlege Review is an independent inquiry led by Julia Cumberlege, Baroness Cumberlege into patient safety concerns arising from the use of specific prescribed medicines and medical devices in the United Kingdom. The review examined historic failures in regulation, clinical practice, and patient support, producing recommendations for reform across health policy and regulatory institutions. Its work intersected with debates involving regulatory agencies, parliamentary committees, healthcare professional bodies, and patient advocacy groups.

Background and purpose

The review was established against a backdrop of high-profile patient safety controversies involving implants and medicines that drew scrutiny from NHS England, the Department of Health and Social Care, and parliamentary bodies including the House of Commons Health and Social Care Committee and the House of Lords Constitution Committee. It built on prior inquiries such as the investigations into the Thalidomide tragedy, the Bristol heart scandal, and the Mid Staffordshire NHS Foundation Trust public inquiry led by Robert Francis (barrister), referencing regulatory histories involving the Medicines and Healthcare products Regulatory Agency and the European Medicines Agency. The purpose was to evaluate patient experiences, systemic failures, and to recommend reforms to safeguard patients and strengthen accountability within institutions like the Care Quality Commission and professional regulators such as the General Medical Council and the Nursing and Midwifery Council.

Scope and methodology

The remit covered three specific areas: pelvic mesh implants, hernia mesh, and the hormone pregnancy tests (HPTs) and other prescribed medicines identified by claimants. The review employed mixed methods, combining qualitative testimonies from affected patients represented by groups including Suffered, The Mesh Survivors Network, and legal claimants linked to firms such as Baxter International and Ethicon (Johnson & Johnson), with quantitative evidence from NHS commissioning data, device registries like the National Joint Registry, and regulatory submissions to bodies including the Medicines and Healthcare products Regulatory Agency and the National Institute for Health and Care Excellence. The methodology involved stakeholder meetings with professional colleges such as the Royal College of Surgeons of England, the Royal College of Obstetricians and Gynaecologists, and the British Medical Association, alongside scrutiny by parliamentary actors including members of the Public Accounts Committee and representatives from devolved administrations like the Scottish Government and the Welsh Government.

Key findings and recommendations

The review identified failures in informed consent processes implicating clinicians certificated through pathways overseen by the General Medical Council and surgical training overseen by the Royal College of Surgeons of England. It found shortcomings in post-market surveillance at the Medicines and Healthcare products Regulatory Agency and gaps in device registries comparable to reforms after the poly implant prothèse scandal in France. Recommendations included creation of a statutory duty of candour enforced by the Care Quality Commission, establishment of a patient safety commissioner analogous to roles in jurisdictions like Australia and Canada, and development of a national adverse event database integrated with systems used by the National Health Service (England) and the Health and Social Care Board (Northern Ireland). The review urged the expansion of independent device registries modelled on the National Joint Registry, mandated shared decision-making frameworks endorsed by bodies such as the Royal College of General Practitioners and funded patient support services similar to those developed following the Grenfell Tower inquiry recommendations on victim support. It recommended legislative changes to confer stronger investigatory powers on the Medicines and Healthcare products Regulatory Agency and greater transparency aligned with standards from the European Union clinical trials and device directives.

Implementation and government response

The government response involved commitments from the Department of Health and Social Care and NHS England to implement many recommendations, with plans for statutory reforms debated in the House of Commons and oversight by the Public Accounts Committee. Health ministers engaged with professional regulators including the General Medical Council and Health and Care Professions Council to update fitness-to-practice frameworks. Some measures prompted procurement reviews involving agencies like NHS Supply Chain and litigation strategy dialogues with the Ministry of Justice. Funding pledges were discussed with the Treasury (United Kingdom) and allocation of resources channelled through NHS bodies and devolved health departments including the Scottish Government and the Welsh Government. Implementation plans referenced standards from the World Health Organization and cooperation with international regulators such as the European Medicines Agency and the U.S. Food and Drug Administration.

Criticism and impact

Criticism of the review and its aftermath came from multiple quarters: patient advocates contended that measures on redress were inadequate compared with settlements in high-profile cases involving corporations like Johnson & Johnson and Boston Scientific, while some professional bodies argued that the proposals risked increasing litigation and regulatory burden for clinicians trained through institutions such as the Royal College of Surgeons of Edinburgh. Legal commentators compared the review’s recommendations to precedents set by inquiries like the HIV Haemophilia Litigation and the Aarhus Convention-related transparency debates. Parliamentary opposition figures and select members of the House of Lords questioned pace of reform. Despite critiques, the review spurred revisions in consent protocols across NHS trusts, amendments to device tracking processes, and the launch of new patient support pilots in collaboration with charities such as Action Against Medical Accidents and Which?.

Subsequent reviews and legacy

The review influenced subsequent inquiries and policy work, informing proposals considered by the Health and Social Care Committee and prompting follow-up audits by the National Audit Office and the Care Quality Commission. It shaped curriculum changes discussed with academic institutions including King's College London, University College London, and Imperial College London medical schools, and inspired comparative studies in journals linked to publishers like BMJ Publishing Group and The Lancet (journal). Internationally, its recommendations were referenced in policy dialogues with regulators such as the Therapeutic Goods Administration and the European Commission. The legacy includes stronger patient voice mechanisms, reforms to device surveillance, and a continuing debate in parliamentary and professional fora about balancing innovation, patient safety, and accountability.

Category:United Kingdom health inquiries Category:Patient safety